Publications by authors named "Silvia Marquez-Megias"
Article Synopsis
- - Adalimumab is a monoclonal antibody used to treat inflammatory bowel disease (IBD), but its effectiveness can vary, making it important to personalize dosing.
- - A study developed two population pharmacokinetic (PopPK) models based on existing literature to improve dosing in IBD patients, using data from 54 patients.
- - Among the models, the one incorporating informative priors performed better, showing less bias and imprecision, and providing greater clinical impact compared to the basic estimated model and the reference model.
Article Synopsis
- * This systematic review analyzed the cost-effectiveness of TDM strategies in managing IBD through 13 studies, assessing their quality with the CHEERS checklist.
- * Results showed that TDM is cost-effective or cost-saving when compared to standard treatment approaches, with reactive TDM preferred over proactive TDM in terms of cost-effectiveness ratios.
Objective: Sirolimus is used in the immunosuppressive therapeutic treatment of kidney transplant patients. The high pharmacokinetic variability of sirolimus makes pharmacokinetic monitoring and dosage individualization of mmunosuppressive therapy a key process to achieve better efficacy results. The availability of a population pharmacokinetic model can be used to provide better pharmacokinetic adjustment of plasma concentrations of sirolimus and thus achieve greater clinical benefit.
View Article and Find Full Text PDFArticle Synopsis
- * This study evaluated different population-pharmacokinetic models of adalimumab to find the best fit for a specific patient population at the General University Hospital of Alicante.
- * Results indicated that two of the six models had the best predictive performance, and simulations suggested that adjusting maintenance doses could help achieve the target drug level of 8 mg/L in at least 75% of patients.